Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. [electronic resource]
Producer: 20120202Description: 299-309 p. digitalISSN:- 1533-4406
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Breast Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Disease Progression
- Epirubicin -- administration & dosage
- Female
- Humans
- Logistic Models
- Mastectomy, Segmental
- Medication Adherence
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Receptor, ErbB-2
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.